Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

BACKGROUND: This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer. METHODS: Patients with a body surface area <1.25, 1.25–1.50, and >1.50...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashima, Yosuke, Ishimoto, Osamu, Miyauchi, Eisaku, Sakakibara, Tomohiro, Harada, Toshiyuki, Usui, Kazuhiro, Inoue, Akira, Sugawara, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518229/
https://www.ncbi.nlm.nih.gov/pubmed/37589158
http://dx.doi.org/10.1111/1759-7714.15076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518229/
https://www.ncbi.nlm.nih.gov/pubmed/37589158
http://dx.doi.org/10.1111/1759-7714.15076

Ejemplares similares